Virax Biolabs Group Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Deferred Revenue (Tables)

Deferred Revenue (Tables)

12 Months Ended

Mar. 31, 2023

Contract liabilities [abstract]

Summary of Deferred Revenue


		As of March 31,
		2023				2022
Deferred Revenue			38,250				—
Total Deferred Revenue			38,250				—